pirfenidone has been researched along with Diffuse Parenchymal Lung Disease in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (6.06) | 29.6817 |
| 2010's | 34 (51.52) | 24.3611 |
| 2020's | 28 (42.42) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Deng, L; Hu, X; Zhang, Y; Zhou, J | 1 |
| Amselem, S; Bonniaud, P; Cadranel, J; Chevereau, M; Clément, A; Cottin, V; Crestani, B; Dufaure-Garé, I; Gondouin, A; Guéguen, S; Israël-Biet, D; Jouneau, S; Marchand-Adam, S; Nunes, H; Reynaud-Gaubert, M; Wemeau, L | 1 |
| Chen, MC; Elenko, E; Harnett, MD; Korth, CC; Lickliter, JD | 1 |
| Axmann, J; Corte, TJ; Cottin, V; Gilberg, F; Kirchgaessler, KU; Kreuter, M; Maher, TM; Molina-Molina, M | 1 |
| Fu, PK; Tseng, CW; Wang, KL; Yen, TH | 1 |
| Liu, X; Qiu, L; Wu, J; Wu, W; Zhang, G | 1 |
| Fares, N; Habr, B; Hajal, J; Layoun, H; Saliba, Y; Smayra, V | 1 |
| Adamali, HI; Chambers, DC; Chaudhuri, N; Cox, PG; Danoff, SK; Dellaripa, PF; Flaherty, KR; Forrest, IA; Gibbons, MA; Glaspole, I; Goldberg, HJ; Golden, J; Gooptu, B; Hurwitz, S; Kolb, M; Lasky, JA; Lynch, DA; Maurer, R; Perrella, MA; Raghu, G; Rosas, IO; Scholand, MB; Solomon, JJ; Spencer, LG; Spino, C; Troy, L; Vassallo, R; Woodhead, FA | 1 |
| Graudal, N; Lindhardsen, J; Nielsen, CT | 1 |
| Hurwitz, S; Maurer, R; Rosas, IO; Solomon, JJ | 1 |
| Gower, WA; Hagood, JS; McKinzie, CJ; Vece, TJ | 1 |
| Aliberti, S; Amati, F; Blasi, F; Gramegna, A; Mantero, M; Polelli, V; Stainer, A | 1 |
| Distler, J; Fischer, A | 1 |
| Huang, H; Li, S; Shao, C; Sun, YX; Xu, K; Xu, ZJ | 1 |
| Chambers, DC; Danoff, SK; Dellaripa, PF; DiFranco, D; Goldberg, HJ; Haynes-Harp, S; Hurwitz, S; Kolb, M; Peters, EB; Rosas, IO; Solomon, JJ; Spino, C; Woodhead, F | 1 |
| Distler, O; Hoffmann-Vold, AM; Maher, TM; Volkmann, ER | 1 |
| Axmann, J; Corte, TJ; Cottin, V; Fischer, A; Gilberg, F; Kirchgaessler, KU; Kreuter, M; Lederer, DJ; Maher, TM; Molina-Molina, M; Samara, K | 1 |
| Oldham, JM | 1 |
| Collins, BF; Raghu, G | 1 |
| Eichinger, M; Heussel, CP; Kahn, N; Kreuter, M; Lars, K; Palmucci, S; Polke, M; Sambataro, D; Sambataro, FM; Sambataro, G; Sarmand, N; Torrisi, SE; Vancheri, C; Wälscher, J | 1 |
| Acharya, N; Dhir, V; Dhooria, S; Jain, S; Mishra, D; Sharma, SK | 1 |
| Li, G; Nong, L; Wang, M; Wang, R | 1 |
| Condos, R; Deshwal, H; Gibson, CD; Kugler, MC; Munger, JS | 1 |
| Kolb, MRJ; Scallan, C; Wongkarnjana, A | 1 |
| McMahan, ZH; Volkmann, ER | 1 |
| De Sadeleer, LJ; Van Raemdonck, D; Verleden, GM; Verleden, SE; Vos, R | 1 |
| Homma, S; Isobe, K; Isshiki, T; Kurosaki, A; Nakamura, Y; Sakamoto, S; Shimizu, H | 1 |
| Altinisik, G; Karasu, U; Ufuk, F | 1 |
| Drakopanagiotakis, F; Markart, P; Wygrecka, M | 1 |
| Baba, T; Hagiwara, E; Ikeda, S; Katano, T; Kitamura, H; Komatsu, S; Misumi, T; Ogura, T; Okabayashi, H; Okuda, R; Sekine, A; Yamakawa, H | 1 |
| Wells, AU | 1 |
| Behr, J; Blaas, S; Bonella, F; Bonnet, R; Claussen, M; Ficker, JH; Frankenberger, M; Freise, J; Grohe, C; Günther, A; Hammerl, P; Held, M; Hummler, S; Johow, J; Kahn, N; Kneidinger, N; Koschel, D; Kreuter, M; Neumeister, W; Neuser, P; Prasse, A; Rabe, KF; Schönfeld, N; Tello, S; Welte, T; Wilkens, H; Wirtz, H | 1 |
| Chen, T; Chen, YN; Hu, Y; Huang, Y; Li, HP; Li, QH; Shi, JY; Wang, XD; Weng, D; Wu, CY; Ye, S; Yin, CS; Zhang, AH; Zhang, Y; Zhou, Y | 1 |
| Inaba, S; Matsumoto, J; Mori, Y; Nagaya, H; Sunohara, K | 1 |
| Behr, J; Kreuter, M; Wälscher, J | 1 |
| Elia, D; Harari, S; Humbert, M | 1 |
| Raghu, G; Richeldi, L | 1 |
| Maeda, S | 1 |
| Chen, Z; Li, XJ; Liao, XP; Lin, H; Xiao, H; Zhang, GF; Zhang, J; Zhang, X | 1 |
| George, PM; Wells, AU | 1 |
| Boehm, PM; Gottlieb, J; Ius, F; Jaksch, P; Klepetko, W; Lambers, C; Lee, S; Ristl, R; Tudorache, I; Welte, T | 1 |
| Homma, S; Kabuki, T; Shibuya, K; Sugino, K | 1 |
| Bergna, M; de Andrade, J; Falk, J; Hallowell, R; Jouneau, S; Kondoh, Y; Morrow, L; Randerath, W; Richeldi, L; Strek, M; Tabaj, G; Varone, F | 1 |
| Cottin, V; Fischer, A; Harari, S; Quaresma, M; Stowasser, S; Wollin, L | 1 |
| Ferrara, G; Ortiz, C; Pesonen, I | 1 |
| Lin, H; Wu, C; Zhang, X | 1 |
| Azuma, A; Fujita, K; Hayashihara, K; Miura, Y; Nei, T; Rin, S; Saito, T; Sekine, A; Takoi, H; Tanaka, T; Tsunoda, Y; Yatagai, Y | 1 |
| Kaminski, N; Rosas, IO | 1 |
| Belloli, EA; Flaherty, KR; Martinez, FJ | 1 |
| Jones, MG; Richeldi, L | 1 |
| Albera, C; Chen, D; Chung, L; Fischer, A; Gorina, E; Khalidi, N; Khanna, D; Raghu, G; Schiopu, E; Seibold, JR; Tagliaferri, M | 1 |
| Bi, YL; Feng, RE; Huang, H; Li, S; Xu, K; Xu, ZJ | 1 |
| Adegunsoye, A; Strek, ME | 1 |
| Chen, S; Chen, Z; Gu, L; Guo, L; Li, T; Sun, F; Tan, X; Wang, X; Ye, S | 1 |
| Araki, K; Hirai, K; Hoshino, K; Igarashi, T; Ishii, N; Kubo, N; Kuwano, H; Saitoh, F; Shirabe, K; Tsukagoshi, M; Watanabe, A; Yamanaka, T | 1 |
| Man, XY; Yang, BB; Zheng, M | 1 |
| Bast, A; den Hartog, GJ; Haenen, GR; Weseler, AR | 1 |
| Demedts, MG; Thomeer, M; Wuyts, WA | 1 |
| Günther, A; Markart, P; von der Beck, D | 1 |
| Luckhardt, TR; Müller-Quernheim, J; Thannickal, VJ | 1 |
| Bajwah, S; Higginson, IJ; Koffman, J; Patel, AS; Peacock, JL; Riley, J; Ross, JR; Wells, AU | 1 |
| Lota, HK; Wells, AU | 1 |
| Hamada, K; Izumi, T; Nagai, S; Shigematsu, M; Taniyama, M; Yamauchi, S | 1 |
| Fukuda, T; Kurasawa, K | 1 |
| Azuma, A | 1 |
| Millar, AB; Poole, AR; Thickett, DR | 1 |
27 review(s) available for pirfenidone and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Progression-Free Survival; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity | 2021 |
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Pyridones; Treatment Outcome | 2023 |
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppression Therapy; Indoles; Kaplan-Meier Estimate; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Risk Factors; Tomography, X-Ray Computed | 2019 |
Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.
Topics: Antibodies, Monoclonal, Humanized; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Pyridones; Randomized Controlled Trials as Topic; Rituximab; Scleroderma, Systemic; Transplantation, Autologous | 2019 |
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
Topics: Animals; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Diseases, Interstitial; Pyridones; Treatment Outcome; Vital Capacity | 2019 |
Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Vital Capacity | 2020 |
An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
Topics: Autoantibodies; Clinical Trials as Topic; Cyclophosphamide; Drugs, Investigational; Humans; Lung Diseases, Interstitial; Mycophenolic Acid; Pyridones; Rituximab; Scleroderma, Diffuse; Scleroderma, Systemic; Treatment Outcome | 2020 |
Advances in lung transplantation for interstitial lung diseases.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Extracorporeal Membrane Oxygenation; Humans; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Nutritional Status; Patient Selection; Perioperative Care; Preoperative Care; Protein Kinase Inhibitors; Pyridones | 2020 |
Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?).
Topics: Disease Progression; Enzyme Inhibitors; Humans; Indoles; Lung Diseases, Interstitial; Observational Studies as Topic; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Pulmonary Hypertension in Parenchymal Lung Diseases: Any Future for New Therapies?
Topics: Antihypertensive Agents; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endpoint Determination; Epoprostenol; Forecasting; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Indoles; Lung Diseases, Interstitial; Phosphodiesterase 5 Inhibitors; Pilot Projects; Protein-Tyrosine Kinases; Pulmonary Disease, Chronic Obstructive; Pyridones | 2018 |
Current approaches to the management of idiopathic pulmonary fibrosis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Middle Aged; Palliative Care; Patient Education as Topic; Practice Guidelines as Topic; Prevalence; Pyridones; Quality of Life; Young Adult | 2017 |
[Perioperative Management of Patients with Pulmonary Comorbidities Undergoing Lung Resection].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Glucocorticoids; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Methylprednisolone; Perioperative Care; Pneumonectomy; Postoperative Complications; Pulmonary Disease, Chronic Obstructive; Pyridones; Respiratory Insufficiency | 2017 |
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
Topics: Disease Progression; Humans; Indoles; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Risk Factors; Treatment Outcome | 2018 |
Fibrosing interstitial lung diseases: knowns and unknowns.
Topics: Disease Progression; Health Status; Humans; Indoles; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Quality of Life; Respiratory System Agents; Risk Factors; Severity of Illness Index; Treatment Outcome | 2019 |
Update in Interstitial Lung Disease 2014.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Doxycycline; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Lymphangioleiomyomatosis; Pyridones; Sarcoidosis, Pulmonary; Sirolimus; Smoking; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha | 2015 |
Recent Advances and Future Needs in Interstitial Lung Diseases.
Topics: Clinical Trials as Topic; Forecasting; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Pyridones; Quality of Life | 2016 |
Therapeutic Approach to Adult Fibrotic Lung Diseases.
Topics: Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Connective Tissue Diseases; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Prognosis; Pyridones | 2016 |
Perioperative management of hepatectomy in patients with interstitial pneumonia: a report of three cases and a literature review.
Topics: Aged; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Hepatectomy; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Male; Mucin-1; Perioperative Care; Postoperative Complications; Pyridones; Respiration Disorders; Tomography, X-Ray Computed | 2017 |
Oxidative stress and antioxidants in interstitial lung disease.
Topics: Acetylcysteine; Antioxidants; Humans; Lung Diseases, Interstitial; Oxidative Stress; Pyridones; Reactive Oxygen Species | 2010 |
Newer modes of treating interstitial lung disease.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Azathioprine; Humans; Lung Diseases, Interstitial; Lung Transplantation; Palliative Care; Pyridones | 2011 |
[Interstitial lung disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Guidelines as Topic; Humans; Lung Diseases, Interstitial; Lymphangioleiomyomatosis; Pyridones; Sarcoidosis; Scleroderma, Systemic | 2011 |
Update in diffuse parenchymal lung disease 2011.
Topics: Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Autoimmunity; Clinical Trials as Topic; Comorbidity; Gastroesophageal Reflux; Homeostasis; Humans; Lung Diseases, Interstitial; Pyridones; Risk Assessment; Sarcoidosis, Pulmonary | 2012 |
Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Cough; Dyspnea; Exercise Test; Fibrosis; Glucocorticoids; Heroin; Humans; Immunologic Factors; Lung; Lung Diseases, Interstitial; Narcotics; Oxygen Inhalation Therapy; Piperazines; Prednisolone; Purines; Pyridones; Quality of Life; Sildenafil Citrate; Sulfones; Thalidomide; Tubulin Modulators | 2013 |
The evolving pharmacotherapy of pulmonary fibrosis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Interstitial Pneumonias; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Sarcoidosis, Pulmonary; Scleroderma, Systemic; Treatment Outcome | 2013 |
[Interstitial pneumonia].
Topics: Apoptosis; Chemokines; Cytokines; Fibrosis; Humans; Immunosuppressive Agents; Inflammation; Interferon-gamma; Lung Diseases, Interstitial; Lung Transplantation; Macrophages; Pyridones; Respiratory Function Tests; Th1 Cells; Th2 Cells; Tomography, X-Ray Computed | 2005 |
[Newly developed therapeutic drugs for idiopathic interstitial pneumonias].
Topics: Acetylcysteine; Drug Design; Drug Therapy, Combination; Humans; Interferon-gamma; Lung Diseases, Interstitial; Prednisolone; Pyridones; Randomized Controlled Trials as Topic | 2006 |
The balance between collagen synthesis and degradation in diffuse lung disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biomarkers; Collagen; Disease Models, Animal; Humans; Inflammation; Interferon-gamma; Lung Diseases, Interstitial; Pulmonary Fibrosis; Pyridones | 2001 |
8 trial(s) available for pirfenidone and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium-Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases.
Topics: Deuterium; Dose-Response Relationship, Drug; Humans; Lung Diseases, Interstitial; Pyridones | 2022 |
Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use.
Topics: Double-Blind Method; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Mycophenolic Acid; Pyridones; Treatment Outcome | 2022 |
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Topics: Adult; Arthritis, Rheumatoid; COVID-19; Double-Blind Method; Humans; Lung Diseases, Interstitial; Pandemics; Treatment Outcome | 2023 |
The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Longitudinal Studies; Lung Diseases, Interstitial; Male; Middle Aged; Pyridones; Risk Factors; United States | 2019 |
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Mycophenolic Acid; Progression-Free Survival; Pulmonary Fibrosis; Pyridones; Respiratory Function Tests; Treatment Outcome; Vital Capacity | 2020 |
Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial.
Topics: Adult; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Middle Aged; Pilot Projects; Pyridones; Scleroderma, Systemic; Treatment Outcome; Vital Capacity | 2020 |
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Early Termination of Clinical Trials; Female; Humans; Intention to Treat Analysis; Lung Diseases, Interstitial; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Respiratory Function Tests; Symptom Assessment | 2021 |
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Mycophenolic Acid; Pyridones; Scleroderma, Systemic; Treatment Outcome | 2016 |
31 other study(ies) available for pirfenidone and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Cyclosporine; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Male; Pyridones | 2021 |
Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort.
Topics: Cohort Studies; France; Humans; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pyridones; Tablets; Treatment Outcome | 2022 |
Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report.
Topics: Autoantibodies; Dermatomyositis; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Piperidines; Pyridones; Pyrimidines; Rituximab | 2021 |
Pirfenidone mitigates TGF-β1-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model.
Topics: Animals; Guinea Pigs; Lung; Lung Diseases, Interstitial; Male; Mice; Myositis; Pulmonary Fibrosis; Pyridones; Transforming Growth Factor beta1 | 2022 |
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease.
Topics: Arthritis, Rheumatoid; Humans; Lung; Lung Diseases, Interstitial; Pyridones | 2023 |
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease - Authors' reply.
Topics: Arthritis, Rheumatoid; Humans; Lung Diseases, Interstitial; Pyridones | 2023 |
Use of pirfenidone in pediatric patients with interstitial lung disease and pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Diseases, Interstitial; Pulmonary Fibrosis; Pyridones | 2023 |
[The clinical experience of pirfenidone based on corticosteroids and immunosuppressant treatment for interstitial pneumonia with autoimmune features].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome | 2019 |
Interstitial lung disease: perhaps unclassifiable, but not untreatable.
Topics: Double-Blind Method; Humans; Lung Diseases, Interstitial; Pyridones | 2020 |
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Topics: Aged; Disease Progression; Female; Humans; Indoles; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Phenotype; Pulmonary Fibrosis; Pyridones; Retrospective Studies; Risk Factors; Tertiary Care Centers; Tomography, X-Ray Computed | 2019 |
Multiple eruptive dermatofibromas aggravated by mycophenolate mofetil and pirfenidone in a patient with systemic sclerosis.
Topics: Antirheumatic Agents; Female; Histiocytoma, Benign Fibrous; Humans; Lung Diseases, Interstitial; Middle Aged; Mycophenolic Acid; Pyridones; Scleroderma, Systemic; Skin; Skin Neoplasms | 2020 |
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Indoles; Lung Diseases, Interstitial; Phenotype; Prognosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Treatment Outcome; Vital Capacity | 2020 |
Effectiveness of pirfenidone for idiopathic pulmonary fibrosis associated with pleuroparenchymal fibroelastosis-like lesions and nonspecific interstitial pneumonia.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Diseases, Interstitial; Pyridones; Retrospective Studies | 2021 |
Pleuroparenchymal fibroelastosis in a patient with systemic sclerosis.
Topics: Aged; Bronchiectasis; Disease Progression; Elastic Tissue; Female; Humans; Lung Diseases, Interstitial; Pleural Diseases; Pulmonary Diffusing Capacity; Pulmonary Fibrosis; Pyridones; Scleroderma, Systemic; Tomography, X-Ray Computed; Vital Capacity | 2021 |
[Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Indoles; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Pyridones; Randomized Controlled Trials as Topic | 2021 |
Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity | 2021 |
Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Early Termination of Clinical Trials; Endpoint Determination; Health Services Needs and Demand; Humans; Idiopathic Pulmonary Fibrosis; Intention to Treat Analysis; Lung Diseases, Interstitial; Patient Selection; Practice Guidelines as Topic; Pyridones; Respiratory Function Tests | 2021 |
The role of pirfenidone in the treatment of interstitial pneumonia with autoimmune features.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pyridones; Retrospective Studies; Vital Capacity | 2022 |
Effects of pirfenidone on renal function in patients with interstitial pneumonia.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Kidney; Kidney Function Tests; Lung Diseases, Interstitial; Male; Middle Aged; Pyridones; Retrospective Studies | 2021 |
Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease.
Topics: Actins; Adult; Case-Control Studies; Cells, Cultured; Female; Fibroblasts; Fibronectins; Glycogen Synthase Kinase 3 beta; Hedgehog Proteins; Humans; Lung; Lung Diseases, Interstitial; Male; MAP Kinase Kinase 4; Middle Aged; Nuclear Proteins; Patched-1 Receptor; Phosphorylation; Pulmonary Fibrosis; Pyridones; Repressor Proteins; Scleroderma, Systemic; Signal Transduction; Smad2 Protein; Tomography, X-Ray Computed; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2018 |
Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy.
Topics: Evidence-Based Medicine; Humans; Immunosuppressive Agents; Immunotherapy; Indoles; Lung Diseases, Interstitial; Phenotype; Pyridones; Risk Assessment; Scleroderma, Systemic | 2018 |
Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis.
Topics: Europe; Female; Humans; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Male; Middle Aged; Postoperative Care; Pyridones; Retrospective Studies; Steroids; Treatment Outcome | 2018 |
Systemic scleroderma-related interstitial pneumonia associated with borderline pulmonary arterial hypertension.
Topics: Aged; Anti-Inflammatory Agents; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Prednisolone; Pulmonary Artery; Pyridones; Pyrimidines; Scleroderma, Limited; Sulfonamides | 2018 |
An Atypical Case of Idiopathic Pulmonary Fibrosis in a Patient from Africa.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Black People; Bronchoscopy; Diagnosis, Differential; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Hospitals, University; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Diseases, Interstitial; Male; Pyridones; Rare Diseases; Respiratory Function Tests; Smokers; Sweden; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3).
Topics: Activating Transcription Factor 3; Adult; Aged; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cell Differentiation; Cell Movement; Cells, Cultured; Disease Models, Animal; Down-Regulation; Female; Fibroblasts; Gene Knockdown Techniques; Humans; Lung; Lung Diseases, Interstitial; Male; Mice, Inbred C57BL; Middle Aged; Myofibroblasts; Pulmonary Fibrosis; Pyridones | 2019 |
Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease.
Topics: Aged; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Pyridones; Recovery of Function; Retrospective Studies; Scleroderma, Diffuse; Scleroderma, Localized; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity | 2014 |
Update in diffuse parenchymal lung disease, 2013.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Disease Progression; Drug Approval; Enzyme Inhibitors; Genomics; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Polymorphism, Genetic; Pyridones; Treatment Outcome; United States; United States Food and Drug Administration | 2015 |
A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: A CARE-compliant article.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Pyridones; Scleroderma, Systemic; Treatment Outcome | 2016 |
Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatomyositis; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Pyridones; Retrospective Studies; Treatment Outcome | 2016 |
Pirfenidone combined with corticosteroids in a patient with systemic lupus erythematosus-associated interstitial lung disease.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Middle Aged; Prednisone; Pyridones | 2017 |
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Gas Analysis; Chronic Disease; Feasibility Studies; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Radiography, Thoracic; Respiratory Function Tests; Scleroderma, Systemic; Time Factors; Treatment Outcome | 2002 |